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Introduction
Mitochondrial dysfunction and consequent cellular ener-
getic failure play a key role in the development of
sepsis-related organs failure. Levosimendan, by a
calcium-sensitizing mechanism increases myocardial
contractility while simultaneously exerting vasodilatory
properties via activation of ATP-dependent potassium
channels (KATP) [1].
Objectives
The aim of the present study was to evaluate the effects
of levosimendan on muscle metabolism compared with
placebo and dobutamine in patients with spetic shock.
Methods
The study was designed as a prospective, double-blind,
placebo-controlled, clinical trial and performed in a Tuni-
sian medical surgical intensive care unit. After achieving
normovolemia and a mean arterial pressure of at least
65 mmHg, 30 septic shock patients were randomized to
one of three intravenous treatment groups: levosimendan
0.2 µg/kg/min (n = 10), dobutamine 5 µg/kg/min (n = 10)
or placebo (n = 10). Systemic hemodynamic monitoring of
the patients included a central venous catheter, a radial
artery catheter and a pulmonary artery catheter. A micro-
dialysis probe was placed into the femoral quadriceps and
samples were collected at baseline (before drugs admin-
stration) and every 6 hours for 3 days. The changes in the
energy-related metabolites lactate, the lactate/pyruvate
ratio, glucose and glycerol were analyzed. concomitantly
with dialysate sampling, the effects on global haemody-
namics, were assessed. Lactate and L/P clearances were
also calculated.
Results
Baseline characteristics, including age, gender, body weight,
and Cause of septic shock, as well as onset time of septic
shock, IGSII, and mortality were not different among
groups. In addition, there was no significant difference
between groups at baseline (H0) in any of the investigated
hemodynamic or MD metabolites variables. Levosimendan
group had a greater decrease in L/P ratio and a greater
increase in MD pyruvate at the 72 th 72th hour compared
with the placebo group (p = 0.043). Tissue lactate clearance
was significantly increased in the levosimendan arm com-
pared with the placebo arm at 54th, 60th and 72th hours
of the study ( H54 p = 0.036 ; H60 p = 0.043 ; H72 p =
0.041). From 48th to 72th hours, Tissue L/P clearance was
significantly higher in levosimendan-treated patients com-
pared with placebo (H48 (p = 0.015), H54 (p = 0.032), H60
(p = 0.016) et à H72 (p = 0.007)). Tissue L/P clearance Tis-
sue L/P clearance was higher in Levosimendan group than
in dobutamine group at 72th hour (p = 0.006).
Conclusions
Our results demonstrate that levosimendan improves
Cellular metabolic alterations.
Our data suggest that levosimendan may protect mito-
chondria from oxidative stress and maintain cellular
energy homeostasis during septic shock by opening
mitochondrial KATP channels.
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